Copyright 2003 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2003
THERAPEUTIC STUDIES in toxic epidermal necrolysis (TEN), a rare but dramatic and life-threatening disease, have recently drawn a considerable amount of attention. Despite (or perhaps due to) the fact that a variety of possible therapeutic modalities have been proposed, usually based on a symptomatic approach and tried in single patients or small series, still no proven and widely accepted treatment regimen exists.
The development of a generally accepted treatment strategy has been hampered by the fact that the condition is part of a larger spectrum of reactive inflammatory skin diseases and thus heterogeneous; that it is rare and life threatening and thus precludes placebo-controlled studies; and that our knowledge on the pathogenic mechanisms involved are still only fragmentary.
Wolff K, Tappeiner G. Treatment of Toxic Epidermal NecrolysisThe Uncertainty Persists but the Fog Is Dispersing. Arch Dermatol. 2003;139(1):85-86. doi:10.1001/archderm.139.1.85